← Back to Search

Heat Shock Protein 90 (Hsp90) Inhibitor

Icapamespib for Glioblastoma (Glio Trial)

Phase 1
Waitlist Available
Research Sponsored by Samus Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
Awards & highlights

Glio Trial Summary

This trial is testing a new drug to see if it's effective in treating brain lesions. It will first test different doses to see what works best, and then test that dose on a larger group of people. The goal is to find the best dose of the drug to move on to the next stage of testing.

Eligible Conditions
  • Glioblastoma
  • Brain Tumor
  • Astrocytoma

Glio Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Icapamespib Plasma Concentration at Time of Surgery
Incidence and severity of adverse events
Camurati-Engelmann Syndrome

Glio Trial Design

2Treatment groups
Experimental Treatment
Group I: dose expansion cohortExperimental Treatment1 Intervention
dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D)
Group II: 20 mg Icapamespib cohortExperimental Treatment1 Intervention
Icapamespib will be administered orally once daily for each 28-day cycle. The initial dose in this trial will be 20 mg

Find a Location

Who is running the clinical trial?

Samus Therapeutics, Inc.Lead Sponsor
8 Previous Clinical Trials
76 Total Patients Enrolled
Michael Silverman, MDStudy DirectorSamus Therapeutics
4 Previous Clinical Trials
323 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
2021. "Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04782609.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top